- Home
- ETON vs NBTX Comparison
ETON vs NBTX Comparison
Compare ETON & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- NBTX
- Stock Information
- Founded
- ETON 2017
- NBTX 2003
- Country
- ETON United States
- NBTX France
- Employees
- ETON N/A
- NBTX N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- NBTX Health Care
- Exchange
- ETON Nasdaq
- NBTX Nasdaq
- Market Cap
- ETON 199.5M
- NBTX 201.9M
- IPO Year
- ETON 2018
- NBTX 2020
- Fundamental
- Price
- ETON $10.02
- NBTX $3.89
- Analyst Decision
- ETON Strong Buy
- NBTX Strong Buy
- Analyst Count
- ETON 3
- NBTX 2
- Target Price
- ETON $12.00
- NBTX $11.50
- AVG Volume (30 Days)
- ETON 212.9K
- NBTX 7.6K
- Earning Date
- ETON 11-12-2024
- NBTX 11-26-2024
- Dividend Yield
- ETON N/A
- NBTX N/A
- EPS Growth
- ETON N/A
- NBTX N/A
- EPS
- ETON N/A
- NBTX N/A
- Revenue
- ETON $34,677,000.00
- NBTX $45,220,186.00
- Revenue This Year
- ETON $19.61
- NBTX N/A
- Revenue Next Year
- ETON $82.71
- NBTX N/A
- P/E Ratio
- ETON N/A
- NBTX N/A
- Revenue Growth
- ETON 5.64
- NBTX 526.17
- 52 Week Low
- ETON $3.03
- NBTX $3.83
- 52 Week High
- ETON $11.11
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- ETON 67.30
- NBTX 40.72
- Support Level
- ETON $8.76
- NBTX $3.83
- Resistance Level
- ETON $11.11
- NBTX $4.55
- Average True Range (ATR)
- ETON 0.66
- NBTX 0.23
- MACD
- ETON 0.10
- NBTX -0.02
- Stochastic Oscillator
- ETON 62.02
- NBTX 30.86
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.